- Previous Close
1.2400 - Open
1.2000 - Bid --
- Ask --
- Day's Range
1.2000 - 1.2250 - 52 Week Range
1.1500 - 1.9600 - Volume
8,183 - Avg. Volume
14,076 - Market Cap (intraday)
14.269M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9200 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
www.synlogictx.comRecent News: SYBX
View MorePerformance Overview: SYBX
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYBX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYBX
View MoreValuation Measures
Market Cap
14.50M
Enterprise Value
-4.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.89k
Price/Book (mrq)
1.14
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.68%
Return on Equity (ttm)
-102.63%
Revenue (ttm)
8k
Net Income Avi to Common (ttm)
-23.36M
Diluted EPS (ttm)
-1.9200
Balance Sheet and Cash Flow
Total Cash (mrq)
18.86M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-25.91M